Financial Data and Key Metrics Changes - Second quarter sales increased by 1% year-over-year, driven by a volume growth of 6% [10] - Adjusted EBITDA for the second quarter was $207 million, a 2% increase compared to the previous year [11] - Adjusted earnings per share (EPS) rose to $0.69, up $0.10 from the prior year, primarily due to EBITDA growth and lower interest expenses [12] Business Line Data and Key Metrics Changes - The growth portfolio experienced a high single-digit increase, while the core portfolio remained essentially flat [11] - The strongest growth came from the EMEA region, attributed to higher volumes of herbicides and branded sales [12] - North America sales declined by 5% due to expected destocking in Canada, although there was solid volume growth in the U.S. [13] Market Data and Key Metrics Changes - Latin America revenues increased slightly as the region concluded the 2024-2025 growing season [12] - Asia faced declines due to lower pricing and volumes, particularly from ongoing destocking in India [13] Company Strategy and Development Direction - The company aims to implement a growth strategy following the normalization of product levels in distribution channels [6] - A new direct sales route in Brazil targeting large corn and soybean growers has been established, with initial customer engagements already underway [7] - The company plans to divest its commercial business in India to regain commercial momentum through a business-to-business model [15][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in reaching 2025 targets and maintaining the 2027 outlook, with expectations for strong performance driven by the growth portfolio [32] - The company anticipates challenges in India due to intense generic competition and a complex regulatory environment, leading to the decision to change operational strategies [14][15] - Management expects to see early results from new product launches and commercial activities in Brazil starting in the third quarter [7][10] Other Important Information - The company has excluded India from revenue guidance due to uncertainties surrounding the divestment process, although reported revenue will still include India until the sale is completed [18][25] - Full-year 2025 guidance remains unchanged across all metrics, with revenue excluding India expected to decline by 2% [19] Q&A Session Summary Question: What should be expected in terms of volume and pricing growth entering 2026? - Management confirmed that 2026 and 2027 targets remain unchanged, with expectations for strong growth driven by the growth portfolio and new active ingredients [36][37] Question: Can you break down the cost savings for Q2? - Cost savings were primarily driven by lower raw material costs, improved fixed cost absorption, and restructuring actions [41][42] Question: What are the sales and EBITDA parameters for the India business in 2024? - The India business is forecasted to generate $70 million in sales for H2 2025, with a need for overall growth of 9% to meet targets [50][51] Question: How is the order book shaping up in Brazil? - Current orders for the second half in Brazil are about 35% to 40% of what is needed, indicating a positive outlook [58] Question: What is the expected impact of the new direct sales program in Brazil? - The impact of the new sales organization is expected to be visible in Q3, with growth anticipated year after year [62] Question: How is the pricing for Rynaxapyr and other products performing? - Rynaxapyr pricing remains relatively flat, with significant pricing headwinds primarily from partner contracts [86] Question: What is the outlook for the pheromones offering? - The full-scale commercial pilot for pheromones is expected to provide insights into performance, with results anticipated by the end of the year [90]

Financial Data and Key Metrics Changes - Second quarter sales increased by 1% year-over-year, driven by a volume growth of 6% [9] - Adjusted EBITDA for the second quarter was $207 million, a 2% increase compared to the prior year [10] - Adjusted earnings per share (EPS) rose to $0.69, up $0.10 from the previous year, primarily due to EBITDA growth and lower interest expenses [11] Business Line Data and Key Metrics Changes - The growth portfolio experienced a high single-digit increase, while the core portfolio remained essentially flat [10] - The second quarter saw a 5% decline in North America sales, attributed to expected destocking in Canada, although the U.S. experienced solid volume growth [12] - EMEA showed strong growth driven by higher volumes of herbicides and branded sales [11] Market Data and Key Metrics Changes - Latin America revenues increased slightly as the region concluded the 2024-2025 growing season [11] - Asia faced declines due to lower pricing and volumes, particularly from ongoing destocking in India [12] Company Strategy and Development Direction - The company is focusing on a growth strategy with lower manufacturing costs and new formulations, particularly in Brazil [6] - A divestment of the commercial business in India is planned to regain commercial momentum through a business-to-business model [14][15] - The company aims to shift its India portfolio towards differentiated technologies with less working capital exposure [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2025 targets and maintaining the 2027 outlook, with expectations for strong performance driven by the growth portfolio [32] - The company anticipates challenges in India but believes the divestment will reduce risk and volatility in future periods [15] Other Important Information - The company expects full-year 2025 adjusted EBITDA to be 1% higher at the midpoint, with revenue guidance excluding India [18] - Free cash flow for 2025 is projected to be between $200 million and $400 million, a decrease from the previous year [30] Q&A Session Summary Question: What should be expected in terms of volume and pricing moving into 2026? - Management confirmed that the 2026 and 2027 targets remain unchanged, with an expected EBITDA of $1.2 billion in 2027, driven by the growth portfolio and new active ingredients [35][36] Question: Can you deconstruct the cost side for Q2 and the second half? - Cost drivers include lower raw material costs, improved fixed cost absorption, and benefits from restructuring actions, with substantial cost tailwinds expected in Q3 and Q4 [41][43] Question: Can you provide parameters on the India business for 2024? - The company forecasted $70 million in sales for H2 2025 from India, with a need for a 9% growth in the business to meet targets [50][51] Question: How is the order book shaping up in Brazil? - Actual orders for the second half in Brazil are about 35% to 40% of what is needed, indicating a positive outlook [58] Question: What is the expectation for the new direct sales program in Brazil? - The impact of the new sales organization in Brazil is expected to be visible in Q3, with growth anticipated year after year [63] Question: What is the outlook for the pheromones offering? - The first full-scale commercial pilot of pheromones is set for Q4, with results expected to inform future revenue projections [93]

Q2 2025 Performance - Revenue increased by 1% to $1,051 million compared to Q2 2024[6], with organic revenue up by 2%[8, 20] - Adjusted EBITDA increased by 2% to $207 million[6, 9] - Adjusted EPS increased by 10% to $0.69[6] - GAAP Net Income decreased by 77% to $67 million[6] - GAAP EPS decreased by 77% to $0.53[6] Regional Performance - North America revenue decreased by 5% to $321 million[21] - Latin America revenue decreased by 17% to $159 million[21] - Asia revenue increased by 1% to $310 million[21] - EMEA revenue increased by 29% to $260 million[21] Financial Outlook - FY 2025 revenue is projected to be between $408 billion and $428 billion, a decrease of 2% year-over-year[24] - FY 2025 Adjusted EBITDA is projected to be between $870 million and $950 million, an increase of 1% year-over-year[24] - FY 2025 Adjusted EPS is projected to be between $326 and $370, flat year-over-year[24] - Q3 2025 revenue is projected to be between $1 billion and $110 billion, a decrease of 1% year-over-year[26] - Q3 2025 Adjusted EBITDA is projected to be between $210 million and $250 million[26] - Q3 2025 Adjusted EPS is projected to be $078 to $098, an increase of 28% year-over-year[26]

Exhibit 99.1 FMC Corporation 2929 Walnut Street Philadelphia, PA 19104 USA 215.299.6000 fmc.com Media contact: Nicole Canning +1.215.299.5916 Nicole.Canning@fmc.com Investor Contact: Curt Brooks +1.215.299.6137 Curt.Brooks@fmc.com FMC Corporation Reports Second Quarter Results at High End of Guidance Range Maintains full year adjusted EBITDA and adjusted EPS guidance; announces sale of India commercial business Second Quarter 2025 Highlights Full-Year Outlook 2 PHILADELPHIA, July 30, 2025 – FMC Corporation ...

Financial Performance - FMC Corporation reported second quarter 2025 revenue of $1.05 billion, an increase of 1 percent compared to the same period in 2024, and a 2 percent organic growth [1][4] - The company’s GAAP net income for the second quarter was $0.53 per diluted share, reflecting a 77 percent decrease from the prior year due to prior year tax incentives [1][4] - Adjusted earnings per diluted share were $0.69, up 10 percent from the second quarter of 2024 [1][4] Revenue Drivers - The increase in revenue was primarily driven by a 6 percent growth in volume, as customers reached target inventory levels for FMC products, despite a 3 percent decline in pricing [2][3] - Sales in North America decreased by 5 percent, while Latin America saw a 1 percent increase, and EMEA sales rose by 29 percent [3][4] Operational Changes - FMC's Board of Directors approved the divestment of its commercial business in India, with plans to maintain participation in the market through a supply agreement with the buyer [6][7] - The revenue from the India commercial business will be classified as held for sale starting in the third quarter, and its earnings will be excluded from adjusted EBITDA and adjusted EPS [7][8] Future Outlook - For the full year 2025, FMC expects revenue excluding India to be between $4.08 billion and $4.28 billion, a decrease of 2 percent at the midpoint compared to the previous year [10][12] - The third quarter revenue forecast, excluding India, is projected to be between $1.00 billion and $1.10 billion, reflecting a 1 percent decline at the midpoint compared to the third quarter of 2024 [8][12] - Adjusted EBITDA for the third quarter is expected to range from $210 million to $250 million, representing a 14 percent increase at the midpoint compared to the prior year [8][12]

Core Viewpoint - The market anticipates FMC will report a year-over-year decline in earnings due to lower revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - FMC is expected to post quarterly earnings of $0.59 per share, reflecting a year-over-year decrease of 6.4% [3]. - Revenues are projected to be $965.4 million, down 7% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.32% lower in the last 30 days, indicating a reassessment by analysts [4]. - A positive Earnings ESP of +2.89% suggests analysts have recently become more optimistic about FMC's earnings prospects [11]. Earnings Surprise History - In the last reported quarter, FMC exceeded expectations by delivering earnings of $0.18 per share against an expected $0.08, resulting in a surprise of +125.00% [12]. - Over the past four quarters, FMC has consistently beaten consensus EPS estimates [13]. Investment Considerations - While FMC shows potential for an earnings beat, other factors may influence stock performance post-earnings release [14][16]. - Monitoring the Earnings ESP and Zacks Rank can provide insights into potential investment opportunities [15].

Core Insights - FMC and Corteva, Inc. are being compared as potential undervalued stocks in the Agriculture - Operations sector [1] - FMC has a Zacks Rank of 2 (Buy) indicating a positive earnings outlook, while Corteva has a Zacks Rank of 3 (Hold) [3][7] Valuation Metrics - FMC has a forward P/E ratio of 13.14, significantly lower than Corteva's forward P/E of 25.71, suggesting FMC is more undervalued [5] - The PEG ratio for FMC is 1.33, while Corteva's PEG ratio is 1.97, indicating FMC's expected EPS growth is more favorable relative to its valuation [5] - FMC's P/B ratio stands at 1.25 compared to Corteva's P/B of 2.15, further supporting FMC's position as the more attractive value option [6] Value Grades - FMC has a Value grade of B, while Corteva has a Value grade of D, highlighting the relative undervaluation of FMC [6]

Core Insights - FMC Corporation has launched its fluindapyr technology with the approval of Tremisia fungicide in Ukraine, marking its first introduction in the EMEA region [1][9] - The approval allows FMC to access over 10 million hectares of Ukrainian farmland, enhancing disease management options for local growers [2][3][9] Product Launch and Market Impact - The Tremisia fungicide is designed to combat significant diseases such as Alternaria, Sclerotinia in sunflowers, and Septoria and rust in wheat [1][9] - Ukraine, being a major exporter of sunflower, oilseed rape, and wheat, is positioned to benefit from this advanced fungicide technology [2] Strategic Partnerships - FMC has partnered with Corteva to expand the use of fluindapyr in the U.S. corn and soybean markets, targeting tough foliar diseases [4] Financial Guidance - The company maintains its 2025 revenue guidance at $4.15-$4.35 billion, with adjusted EBITDA projected at $870-$950 million, reflecting a 1% increase at the midpoint [5] - Adjusted EPS remains unchanged at $3.26-$3.70, and free cash flow is expected to be between $200 million and $400 million [5] Stock Performance - FMC's stock has declined by 21.3% over the past year, contrasting with the industry's growth of 10.3% [6]

Core Points - FMC Corporation has received regulatory approval for its Tremisia® fungicide in Ukraine, marking the introduction of its fluindapyr technology in the EMEA region [1][2] - The approval allows the use of Tremisia® on over 10 million hectares of farmland in Ukraine, specifically targeting oilseed rape, sunflower, and wheat [1][2] - Tremisia® fungicide combines fluindapyr with flutriafol, providing a dual mode of action against significant crop diseases [2][3] Company Overview - FMC Corporation is a global agricultural sciences company focused on providing innovative crop protection solutions to help growers meet the demands of a growing population [4] - The company is committed to developing new active ingredients and technologies that are environmentally sustainable [4] Market Significance - Ukraine is one of the largest exporters of sunflower, oilseed rape, and wheat, making it a strategically important agricultural market for FMC [2][3] - The introduction of Tremisia® fungicide fills a critical gap in disease management for Ukrainian growers, enhancing crop productivity in intensive cropping systems [3]

Group 1 - The article expresses a shift in sentiment regarding FMC Corporation (NYSE: FMC), moving from a positive outlook to a more cautious stance on its investment potential [1] - The author highlights the importance of careful investment for retail value investors who may be risk-averse but still seek opportunities [1] Group 2 - The author has a background in teaching and consulting, indicating a strong understanding of business and investment principles [1] - The article does not disclose any current stock positions or plans to initiate positions in the mentioned companies, emphasizing an unbiased perspective [2]